Merus NV (MRUS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Merus NV (MRUS)
Company Performance

Current Price

as of Oct 16, 2024

$52.30

P/E Ratio

N/A

Market Cap

$3.57B

Description

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Metrics

Overview

  • HQUtrecht, UT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerMRUS
  • Price$52.3+1.85%

Trading Information

  • Market Cap$3.57B
  • Float86.83%
  • Average Daily Volume (1m)582,110
  • Average Daily Volume (3m)507,722
  • EPS-$2.87

Company

  • Revenue$35.19M
  • Rev Growth (1yr)-30.01%
  • Net Income-$50.04M
  • Gross MarginN/A
  • EBITDA Margin-869.26%
  • EBITDA-$63.73M
  • EV$2.88B
  • EV/Revenue81.93
  • P/EN/A
  • P/S91.92
  • P/B4.75
Documents